Zalypsis (PM00104) / PharmaMar - LARVOL DELTA

Translating molecular insights into clinical success: alkaloid-based therapies for leukemia. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "This review discusses several potent alkaloids, such as homoharringtonine, chaetominine, matrine, and jerantinine B, which induce apoptosis, cell cycle arrest, and autophagy and inhibit signaling pathways including PI3K/Akt/mTOR, MAPK, and NF-κB...In addition, targeting leukemia stem cells (LSCs) with alkaloids such as zalypsis offers promise due to its ability to induce apoptosis without significantly affecting normal hematopoietic stem cells...For example, jerantinine B targets AML cells, while vincristine has shown success in lymphocytic leukemia...However, adverse effects such as neutropenia and hepatotoxicity necessitate careful management. Collectively, these findings emphasize the need for further research into alkaloid-based combination therapies to enhance efficacy and minimize toxicity, providing a promising avenue for innovative leukemia treatments."

Journal • Review • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Hepatology • Leukemia • Neutropenia • Oncology • FLT3

Marine Power on Cancer: Drugs, Lead Compounds, and Mechanisms. (PubMed, Mar Drugs) - "This review provides a summary of the anticancer effects and mechanisms of action of selected marine compounds, including cytarabine, eribulin, marizomib, plitidepsin, trabectedin, zalypsis, adcetris, and OKI-179. The future development of anticancer marine drugs requires innovative biochemical biology approaches and introduction of novel therapeutic targets, as well as efficient isolation and synthesis of marine-derived natural compounds and derivatives."

Journal • Review • Breast Cancer • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • Solid Tumor

A Phase I Study of Zalypsis (PM00104) in Subjects With Advanced Malignant Solid Tumors or Lymphoma (clinicaltrials.gov) - P1; N=12; Terminated; Sponsor: PharmaMar; N=35 ➔ 12

Enrollment change • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor • TNNI3

"Synergistic DNA-damaging effect in multiple myeloma with the combination of zalypsis, bortezomib and dexamethasone haematologica.org/content/102/1 …" - Philip McCarthy, ‏@PLMcCarthyMD

Clinical